Shenzhen Kexing Pharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 


«12345678910111213...2223»
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
    Trial primary completion date, IO biomarker:  EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma (clinicaltrials.gov) -  Feb 4, 2025   
    P2,  N=30, Recruiting, 
    Recruiting --> Suspended Trial primary completion date: Dec 2024 --> Mar 2025
  • ||||||||||  CPO301 / CSPC Pharma, SYH2051 / CSPC Pharma
    New P1/2 trial, Monotherapy:  Clinical Trial of SYS6010 (clinicaltrials.gov) -  Jan 15, 2025   
    P1/2,  N=410, Not yet recruiting, 
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, utidelone IV (UTD1) / Beijing Biostar Technologies
    Journal, Real-world evidence, Real-world, Metastases:  Real world analysis of the efficacy and safety of eribulin compared to utidelone in combination with capecitabine for the treatment of metastatic breast cancer. (Pubmed Central) -  Dec 20, 2024   
    In conclusion, either utidelone/capecitabine or eribulin chemotherapy may result in a survival benefit with a tolerable adverse effect profile and favorable safety profile in patients with metastatic breast cancer. The first-line use of eribulin resulted in better PFS and ORR than posterior-line use, and the combination of utidelone/capecitabine represents a more efficacious approach in the advanced first-line therapy of breast cancer.
  • ||||||||||  Review, Journal, BRCA Biomarker, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker:  Targeted and cytotoxic inhibitors used in the treatment of breast cancer. (Pubmed Central) -  Dec 18, 2024   
    Patients with ER-positive tumors are treated with 5-10 years of endocrine therapy and chemotherapy. For patients with metastatic breast cancer, standard first-line and follow-up therapy options include targeted approaches such as CDK4/6 inhibitors, PI3K inhibitors, PARP inhibitors, and anti-PDL1 immunotherapy, depending on the tumor type and molecular profile.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, Aliqopa (copanlisib) / Bayer
    Trial completion date, Trial primary completion date:  Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer (clinicaltrials.gov) -  Dec 18, 2024   
    P1/2,  N=106, Active, not recruiting, 
    For patients with metastatic breast cancer, standard first-line and follow-up therapy options include targeted approaches such as CDK4/6 inhibitors, PI3K inhibitors, PARP inhibitors, and anti-PDL1 immunotherapy, depending on the tumor type and molecular profile. Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Preclinical, Journal:  Establishment and characterization of the novel myxofibrosarcoma cell line, SMU-MFS. (Pubmed Central) -  Dec 3, 2024   
    Furthermore, the cells exhibited low chemosensitivity to doxorubicin, eribulin, and pazopanib, which are used to inhibit metastatic progression. In addition, of the four mice inoculated with SMU-MFS cells, tumors developed in two mice after 8
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
    Trial primary completion date:  A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas (clinicaltrials.gov) -  Dec 3, 2024   
    P2,  N=57, Active, not recruiting, 
    In addition, of the four mice inoculated with SMU-MFS cells, tumors developed in two mice after 8 Trial primary completion date: Aug 2025 --> Jul 2024
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Journal, IO biomarker:  Low-Dose Eribulin Promotes NK Cell-Mediated Therapeutic Efficacy in Bladder Cancer. (Pubmed Central) -  Nov 27, 2024   
    These findings are paradigm-shifting given that chemotherapy is traditionally considered immunosuppressive. Our study reveals the novel effect of low-dose eribulin chemotherapy in inhibiting bladder tumor growth by enhancing anti-tumor NK cell immunity, challenging previous assumptions and opening new therapeutic approaches to improve antitumor immunity.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Metastases:  LEADER: Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma (clinicaltrials.gov) -  Nov 25, 2024   
    P1/2,  N=30, Active, not recruiting, 
    Our study reveals the novel effect of low-dose eribulin chemotherapy in inhibiting bladder tumor growth by enhancing anti-tumor NK cell immunity, challenging previous assumptions and opening new therapeutic approaches to improve antitumor immunity. Trial completion date: Jun 2023 --> Dec 2024
  • ||||||||||  eribulin liposomal (E7389-LF) / Eisai, Ono Pharma
    P1/2 data, P2 data, Journal, Combination therapy, PD(L)-1 Biomarker, IO biomarker:  Phase 1b/2 study of the liposomal formulation of eribulin (E7389-LF) in combination with nivolumab: Results from the phase 2 esophageal cancer cohort. (Pubmed Central) -  Nov 15, 2024   
    P1b/2
    Although we could detect higher concentrations of eribulin in brain tissue where BBB was disrupted, intracerebral eribulin levels were not sufficient to predict eribulin would have consistent clinically meaningful activity against tumors in the brain. E7389-LF plus nivolumab showed antitumor activity in patients with unresectable and pretreated esophageal cancer and should be evaluated further in a broader population.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    A PHASE 1B TRIAL OF PREOPERATIVE ERIBULIN AND RADIATION FOR RETROPERITONEAL LIPOSARCOMA () -  Nov 9, 2024 - Abstract #CTOS2024CTOS_597;    
    P1
    A preoperative chemoradiation protocol of eribulin in combination with IMRT showed a manageable safety profile and warrants additional prospective evaluation for treatment of RPLPS. (This investigator-initiated trial was supported by Eisai Inc.; ClinicalTrials.gov number, NCT03361436.)
  • ||||||||||  Yondelis (trabectedin) / PharmaMar, J&J, Halaven (eribulin mesylate) / Eisai
    CURRENT SCENARIO OF SARCOMA CLINICAL TRIALS IN SOUTH AMERICA: A REPORT BY THE LACOG SARCOMA GROUP () -  Nov 9, 2024 - Abstract #CTOS2024CTOS_428;    
    Moreover, the minority of new drugs approved by the FDA in the past 15 years have been evaluated in trials that enrolled patients in South America. This underrepresentation underscores the need for increased efforts to promote oncology clinical trials in our region to allow for equitable access to novel treatments.